According to The Insight Partners' research, the Middle East and Africa Epigenetics Market was valued at US$ 269.2 Million in 2024 and is expected to reach US$ 710.0 Million by 2031, registering a CAGR of 14.8% from 2025 to 2031.
Rising global prevalence of cancer and advances in CRISPR-Based epigenome editing technologies are among the critical factors attributed to driving the Middle East & Africa epigenetics market growth.
The increasing global prevalence of cancer drives the epigenetics market, as epigenetic mechanisms emphasize many oncogenic processes, fueling the need for novel diagnostics and therapeutics. According to the World Health Organization, cancer accounted for ~10 million deaths worldwide in 2020, with projections indicating over 35 million new cases by 2050 due to an aging population and lifestyle factors. Cancer prevalence and incidence in Saudi Arabia are rising rapidly as the population ages and lifestyles shift. The crude incidence rate hovers around 66–67 per 100,000 population, with Saudi nationals experiencing higher rates than non-Saudi residents. Breast, colorectal, and thyroid cancers are the most common.
Epigenetic alterations, such as DNA hypermethylation and histone modifications, frequently drive tumorigenesis; for instance, in colorectal cancer, promoter methylation of genes such as MLH1 contributes to microsatellite instability in 15-20% of sporadic cases. This has led to the adoption of epigenetic agents such as azacitidine, a DNA methyltransferase inhibitor approved for myelodysplastic syndromes, which achieves complete response rates of 15-20% by reversing aberrant methylation patterns. Additionally, vorinostat, a histone deacetylase inhibitor used in cutaneous T-cell lymphoma, demonstrates objective response rates of ~30% in clinical trials. Epigenetics influences other diseases; in type 2 diabetes, environmental exposures alter methylation at loci such as PPARGC1A, increasing risk by up to 25% in exposed populations. Epigenetic biomarkers, such as MGMT promoter methylation in glioblastoma, predict temozolomide response in 40-45% of patients, enhancing survival outcomes. In breast cancer, GSTP1 methylation correlates with prognosis, aiding risk stratification. These advancements address disparities, as low-income regions face 70% of global cancer mortality, prompting the development of cost-effective liquid biopsies with 80-90% sensitivity for early detection via cell-free DNA methylation. Overall, epigenetics toward mainstream clinical integration, potentially mitigating the projected increase in cancer burden through targeted epi-therapies and preventive strategies.
On the contrary, the high development and implementation costs hamper the growth of the Middle East & Africa epigenetics market.
Middle East and Africa Epigenetics Market Segmentation Analysis:
- By Product and Services, the Middle East and Africa Epigenetics Market is segmented into Kits and Reagents, Instruments and Accessories, Enzymes, and Services. The Kits and Reagents segment is projected to expand at a CAGR of 14.6% during 2025 - 2031.
- By Application, the Middle East and Africa Epigenetics Market is segmented into Oncology and Non-Oncology. The Oncology segment is projected to expand at a CAGR of 15.0% during 2025 - 2031.
- By Technology, the Middle East and Africa Epigenetics Market is segmented into DNA Methylation Analysis, Chromatin Immunoprecipitation Sequencing (ChIP-Seq), Cleavage Under Targets and Tagmentation (CUT and Tag), Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-Seq), Histone Modification Analysis, RNA Epigenetics, Single-cell Epigenomic Assays, and Others. The DNA Methylation Analysis segment is projected to expand at a CAGR of 15.1% during 2025 - 2031.
- By End User, the Middle East and Africa Epigenetics Market is segmented into Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, and Others. The Pharmaceutical and Biotechnology Companies segment is projected to expand at a CAGR of 15.1% during 2025 - 2031.
By country, the Middle East and Africa Epigenetics Market is categorized into Saudi Arabia, South Africa, United Arab Emirates, Rest of Middle East and Africa. South Africa is projected to expand at a CAGR of 15.1% during 2025 - 2031.
Key players operating in the Epigenetics Market are QIAGEN NV, Merck KGaA, Revvity Inc, Agilent Technologies Inc, Abcam Plc, Promega Corp, Oxford Nanopore Technologies, Thermo Fisher Scientific Inc., Active Motif, EpiGentek Group Inc, among others.
- In Jun-2025, SeqOne announced a strategic collaboration with Agilent to enhance the analysis of liquid biopsy data for oncology. This partnership will deliver two powerful, integrated solutions, SomaMethyl and SomaLBx, optimized for Agilent's cutting-edge Avida Cancer panels and integrated into SeqOne's advanced bioinformatics platform to provide molecular labs with streamlined and robust data analysis capabilities.
- In Jan-2023, QIAGEN N.V. announced launching "EZ2 Connct MDx" intended for use in diagnostic laboratories, making the IVD platform for automated sample processing available for widescale use 18 months after availability for research
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com